Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Mixed chimerism in SCT: conflict or peaceful coexistence?

Bone Marrow Transplantation volume 42, pages 297–310 (2008)Cite this article

Abstract

Stem cell transplants that follow both myeloablative and non-myeloablative conditioning regimens can result in states of mixed chimerism, which can be stable over time. With widespread availability of Y chromosome FISH in sex-mismatched transplantation and DNA-based methodologies for analysis of chimerism in other donor–recipient pairs, further insights have been gained regarding the implications of the mixed chimeric state. In transplants performed for inherited and acquired marrow failure disorders, disease status can be improved with only 10–20% donor cells, and it appears that stable mixed chimerism at that level is an acceptable outcome often leading to a state of tolerance, but an increasing level of recipient cells often precedes graft rejection. In transplants performed for malignant conditions, increasing levels of mixed chimerism may indicate disease relapse, but some cases with stable levels of mixed chimerism have been compatible with prolonged remission states. Understanding when mixed chimerism is an indication of secondary graft failure or impending graft rejection vs a state of tolerance and ongoing propensity for the establishment of a graft-vs-tumor effect is often difficult with currently available technologies and immunologic assays. The ability to understand the implication of mixed chimerism of multiple cell lineages and of varied lymphocyte subsets will remain important areas for future research to best harness the immunologic and other therapeutic benefits of allogeneic transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Lindemans MF . Chimera; Encyclopedia Mythica Online, available at http://www.pantheon.org/articles/c/chimera.html 3 March 1997, modified on 22 December 1999.

  2. Lion T . Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 2007; 134: 197–216.

    CAS  PubMed  Google Scholar 

  3. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T . How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107–119.

    CAS  PubMed  Google Scholar 

  4. Knowlton RG, Brown VA, Braman JC, Barker D, Schumm JW, Murray C et al. Use of highly polymorphic DNA probes for genotypic analysis following bone marrow transplantation. Blood 1986; 68: 78–85.

    Google Scholar 

  5. Bader P, Kreyenberg H . Analysis of chimerism after stem cell transplantation. Methods Mol Med 2004; 91: 247–264.

    CAS  PubMed  Google Scholar 

  6. Beck O, Seidl C, Lehrnbecher T, Kreyenberg H, Schwabe D, Klingebiel T et al. Quantification of chimerism within peripheral blood, bone marrow and purified leukocyte subsets: comparison of singleplex and multiplex PCR amplification of short tandem repeat (STR) loci. Eur J Haematol 2006; 76: 237–244.

    CAS  PubMed  Google Scholar 

  7. Willasch A, Schneider G, Reincke BS, Shayegi N, Kreyenberg H, Kuci S et al. Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurement. Lab Hematol 2007; 13: 73–84.

    CAS  PubMed  Google Scholar 

  8. Zhou M, Sheldon S, Akel N, Killeen AA . Chromosomal aneuploidy in leukemic blast crisis: a potential source of error in interpretation of bone marrow engraftment analysis by VNTR amplification. Mol Diagn 1999; 4: 153–157.

    CAS  PubMed  Google Scholar 

  9. Endler G, Greinix H, Winkler K, Mitterbauer G, Mannhalter C . Genetic fingerprinting in mouthwashes of patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 95–98.

    CAS  PubMed  Google Scholar 

  10. Metaxas Y, Zeiser R, Schmitt-Graeff A, Waterhouse M, Faber P, Follo M et al. Human hematopoietic cell transplantation results in generation of donor-derived epithelial cells. Leukemia 2005; 19: 1287–1289.

    CAS  PubMed  Google Scholar 

  11. Imanishi D, Miyazaki Y, Yamasaki R, Sawayama Y, Taguchi J, Tsushima H et al. Donor-derived DNA in fingernails among recipients of allogeneic hematopoietic stem-cell transplants. Blood 2007; 110: 2231–2234.

    CAS  PubMed  Google Scholar 

  12. Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B . Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci USA 2003; 100: 1364–1369.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Spyridonidis A, Schmitt-Gräff A, Tomann T, Dwenger A, Follo M et al. Epithelial tissue chimerism after human hematopoietic cell transplantation is a real phenomenon. Am J Pathol 2004; 164: 1147–1155.

    PubMed  PubMed Central  Google Scholar 

  14. Spyridonidis A, Mertelsmann R, Finke J . Hematopoietic stem cell transplantation: more than just hematopoietic? J Cancer Res Clin Oncol 2004; 130: 127–134.

    PubMed  Google Scholar 

  15. Hong YC, Liu HM, Chen PS, Chen YJ, Lyou JY, Hu HY et al. Hair follicle: a reliable source of recipient origin after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 871–874.

    CAS  PubMed  Google Scholar 

  16. Schumm M, Feuchtinger T, Pfeiffer M, Hoelle W, Bethge W, Ebinger M et al. Flow cytometry with anti-HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplant 2007; 39: 767–773.

    CAS  PubMed  Google Scholar 

  17. Khan F, Agarwal A, Agrawal S . Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant 2004; 34: 1–12.

    CAS  PubMed  Google Scholar 

  18. Goussetis E, Spiropoulos A, Theodosaki M, Paterakis G, Perieteri I, Kitra V et al. Culture of bone marrow CD105+ cells allows selection of pure BM-stromal cells for chimerism studies in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 36: 557–559.

    CAS  PubMed  Google Scholar 

  19. Petit T, Raynal B, Socie G, Landman-Parker J, Bourhis JH, Gluckman E et al. Highly sensitive polymerase chain reaction methods show the frequent survival of residual recipient multipotent progenitors after non-T-cell-depleted bone marrow transplantation. Blood 1994; 84: 3575–3583.

    CAS  PubMed  Google Scholar 

  20. Landman-Parker J, Socie G, Petit T, Raynal B, Bourhis JH, Pico J et al. Detection of recipient cells after non T-cell depleted bone marrow transplantation for leukemia by PCR amplification of minisatellites or of a Y chromosome marker has a different prognostic value. Leukemia 1994; 8: 1989–1994.

    CAS  PubMed  Google Scholar 

  21. Viard F, Merel P, Bilhou-Nabera C, Marit G, Comeau F, Gharbi MJ et al. Mixed chimerism after sex-mismatched allogeneic BMT: evaluation of two molecular techniques. Bone Marrow Transplant 1993; 11: 27–31.

    CAS  PubMed  Google Scholar 

  22. Nesci S, Manna M, Andreani M, Fattorini P, Graziosi G, Lucarelli G . Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 143–146.

    CAS  PubMed  Google Scholar 

  23. Lucarelli G, Gaziev J . Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22: 53–63.

    PubMed  Google Scholar 

  24. Wu CJ, Gladwin M, Tisdale J, Hsieh M, Law T, Biernacki M et al. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol 2007; 139: 504–507.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665–673.

    CAS  PubMed  Google Scholar 

  26. Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W et al. Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood 2005; 106: 3639–3645.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749–2756.

    CAS  PubMed  Google Scholar 

  28. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC . Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35: 171–177.

    CAS  PubMed  Google Scholar 

  29. Saito AM, Chiba S, Ogawa S, Kanda Y, Hirai H, Kurokawa M . Long-term sustained mixed chimerism after allogeneic stem cell transplantation in a patient with severe aplastic anemia. Intern Med 2007; 46: 1923–1926.

    PubMed  Google Scholar 

  30. Thiele J, Wickenhauser C, Kvasnicka HM, Varus E, Kleppe S, Beelen DW et al. Mixed chimerism of bone marrow CD34+ progenitor cells (genotyping, bcr/abl analysis) after allogeneic transplantation for chronic myelogenous leukemia. Transplantation 2002; 74: 982–986.

    PubMed  Google Scholar 

  31. Thiede C, Bornhäuser M, Oelschlägel U, Brendel C, Leo R, Daxberger H et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001; 15: 293–302.

    CAS  PubMed  Google Scholar 

  32. Mattson J, Uzunel M, Tammik L, Aschan J, Ringdén O . Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976–1985.

    Google Scholar 

  33. Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF . Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39: 285–291.

    CAS  PubMed  Google Scholar 

  34. Reddiconto G, Chiusolo P, Fiorinin A, Farina G, Sorà F, Leone G et al. Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation. Leuk Lymphoma 2007; 48: 2054–2057.

    CAS  PubMed  Google Scholar 

  35. Nasilowska-Adamska B, Majewski M, Seferynska I, Szczepinski A, Tomaszewska A, Prochorec-Sobieszek M et al. Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT. Ann Transplant 2007; 12: 33–38.

    CAS  PubMed  Google Scholar 

  36. Gassmann W, Uharek L, Wottge HU, Schmitz N, Löffler H, Meuller-Ruchholtz W . Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation. Blood 1988; 72: 1574–1579.

    CAS  PubMed  Google Scholar 

  37. Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 805–812.

    CAS  PubMed  Google Scholar 

  38. Dey BR, Shaffer J, Yee AJ, McAffee S, Caron M, Power K et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40: 19–27.

    CAS  PubMed  Google Scholar 

  39. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF . Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007; 92: 1004–1006.

    PubMed  Google Scholar 

  40. Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S et al. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 2007; 82: 873–880.

    CAS  PubMed  Google Scholar 

  41. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993–2003.

    PubMed  Google Scholar 

  42. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320–329.

    PubMed  Google Scholar 

  43. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D . Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007; 318: 1296–1299.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood 1990; 75: 296–304.

    CAS  PubMed  Google Scholar 

  45. Rodríguez-Luaces M, Ferrá C, Martín-Henao G, Berlanga JJ, Grañena A, Gallardo D . Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back. Eur J Haematol 2004; 73: 162–168.

    PubMed  Google Scholar 

  46. Chao NJ, Koh LP, Long GD, Gasparetto C, Horwitz M, Morris A et al. Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biol Blood Marrow Transplant 2004; 10: 569–575.

    PubMed  Google Scholar 

  47. Khee WH, Chye PT, Hoe TC, Fung HG, Khiang HK, Tee GY . Autologous recovery with protractedly undetectable donor chimerisms can precede stable donor engraftment in a nonmyeloablative cord blood transplant. Int J Hematol 2003; 78: 73–75.

    PubMed  Google Scholar 

  48. Thiele J, Wickenhauser C, Kvasnicka HM, Varus E, Schneider C, Müller H et al. Mixed chimerism of erythro-and megakaryopoiesis following allogeneic bone marrow transplantation. Acta Haematol 2003; 109: 176–183.

    CAS  PubMed  Google Scholar 

  49. Sobecks RM, Ball EJ, Askar M, Theil KS, Rybicki LA, Thomas D et al. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 709–714.

    CAS  PubMed  Google Scholar 

  50. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825–3827.

    CAS  PubMed  Google Scholar 

  51. Cho SG, Shuto Y, Soda Y, Nakazaki Y, Izawa K, Uchimaru K et al. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation. Exp Hematol 2004; 32: 1246–1254.

    CAS  PubMed  Google Scholar 

  52. Mints M, Jansson M, Sadeghi B, Westgren M, Uzunel M, Hassan M et al. Endometrial endothelial cells are derived from donor stem cells in an bone marrow transplant recipient. Hum Reprod 2008; 23: 139–143.

    CAS  PubMed  Google Scholar 

  53. Pozzi S, Lisini D, Podesta M, Bernardo ME, Sessarego N, Piaggio G et al. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp Hematol 2006; 34: 934–942.

    CAS  PubMed  Google Scholar 

  54. Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC et al. Engraftment capacity of mesenchymal cells following hematopoieitc stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 2006; 20: 329–335.

    CAS  PubMed  Google Scholar 

  55. Lee JJ, Nam CE, Kook H, Maciejewski JP, Kim YK, Chung IJ et al. Constitution and telomere dynamics of bone marrow stromal cells in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2003; 32: 947–952.

    PubMed  Google Scholar 

  56. Thiele J, Varus E, Wickenhauser C, Kvasnicka HM, Lorenzen J, Gramley F et al. Mixed chimerism of cardiomyocytes and vessels after allogeneic bone marrow and stem-cell transplantation in comparison with cardiac allografts. Transplantation 2004; 77: 1902–1905.

    PubMed  Google Scholar 

  57. Cilloni D, Carol-Stella C, Falzetti F, Sammarelli G, Regazzi E, Colla S et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 2000; 96: 3637–3643.

    CAS  PubMed  Google Scholar 

  58. Thiele J, Varus E, Siebolts U, Kvasnicka HM, Wickenhauser C, Metz KA et al. Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation. Histol Histopathol 2007; 22: 365–372.

    CAS  PubMed  Google Scholar 

  59. Kvasnicka HM, Wickenhauser C, Thiele J, Varus E, Hamm K, Beelen DW et al. Mixed chimerism of bone marrow vessels (endothelial cell, myofibroblasts) following allogeneic transplantation for chronic myelogenous leukemia. Leuk Lymphoma 2003; 44: 321–328.

    PubMed  Google Scholar 

  60. Marino R, Martinez C, Boyd K, Dominici M, Hofmann TJ, Horwitz EM . Transplantable marrow osteoprogenitors engraft in discrete saturable sites in the marrow microenvironment. Exp Hematol 2008; 36: 360–368.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510–517.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Perreault C, Pelletier M, Belanger R, Boileau J, Bonny Y, David M et al. Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol 1985; 60: 253–260.

    CAS  PubMed  Google Scholar 

  63. Emile JF, Haddad E, Fraitag S, Canioni D, Fischer A, Brousse N . Detection of donor-derived Langerhans cells in MHC class II immunodeficient patients after allogeneic bone marrow transplantation. Br J Haematol 1997; 98: 480–484.

    CAS  PubMed  Google Scholar 

  64. Carbonaro DA, Jin X, Cotoi D, Mi T, Yu XJ, Skelton DC et al. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunological reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion. Blood 2008; 111: 5745–5754.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Weng L, Dyson J, Dazzi F . Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment. Proc Natl Acad Sci USA 2007; 104: 8415–8420.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S . et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144–1150.

    CAS  PubMed  Google Scholar 

  67. He KM, Ma Y, Wang S, Min WP, Zhong R, Jevnikar A et al. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance. Eur J Immunol 2007; 37: 3455–3466.

    CAS  PubMed  Google Scholar 

  68. Haspel RL, Ballen KK . Double cord blood transplants: filling a niche? Stem Cell Rev 2006; 2: 81–86.

    PubMed  Google Scholar 

  69. Graves SS, Hogan W, Kuhr CS, Diaconescu R, Harkey MA, Georges GE et al. Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning. Blood 2007; 110: 418–423.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Stumph J, Vnencak-Jones CL, Koyama T, Frangoul H . Comparison of peripheral blood and bone marrow samples for detection of post transplant mixed chimerism. Bone Marrow Transplant 2008; 4: 589–590.

    Google Scholar 

  71. O'Reilly J, Meyer B, Stoner M, Erber W, Herrmann R, Davies J . Very early analysis of graft establishment after allogeneic bone marrow transplantation using the polymerase chain reaction. Brit J Haematol 1993; 85: 169–172.

    CAS  Google Scholar 

  72. Zeiser R, Spyridonidis A, Wäsch R, Ihorst G, Grüllich C, Bertz H et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005; 19: 814–821.

    CAS  PubMed  Google Scholar 

  73. Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M et al. Delayed attainment of full donor chimerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007; 38: 517–526.

    Google Scholar 

  74. Nikolic B, Sykes M . Mixed hematopoietic chimerism and transplantation tolerance. Immunol Res 1997; 16: 217–228.

    CAS  PubMed  Google Scholar 

  75. Sykes M . Immune tolerance: mechanisms and application in clinical transplantation. J Intern Med 2007; 262: 288–310.

    CAS  PubMed  Google Scholar 

  76. Strober S . Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Blood Cells Mol Dis 2008; 40: 48–54.

    PubMed  Google Scholar 

  77. Chiang KY, Lazarus HM . Should we be performing more combined hematopoietic stem cell plus solid organ transplants? Bone Marrow Transplant 2003; 31: 633–642.

    CAS  PubMed  Google Scholar 

  78. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362–368.

    CAS  PubMed  Google Scholar 

  79. Pree I, Wekerle T . Inducing mixed chimerism and transplantation tolerance through allogeneic bone marrow transplantation with costimulation blockade. Methods Mol Biol 2007; 380: 391–403.

    CAS  PubMed  Google Scholar 

  80. Mache CJ, Schwinger W, Spendel S, Zach O, Regauer S, Ring E . Skin transplantation to monitor clinical donor-related tolerance in mixed hematopoietic chimerism. Pediatr Transplant 2006; 10: 128–131.

    PubMed  Google Scholar 

  81. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Khan PM, Vossen JM . Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood 1993; 82: 1921–1928.

    CAS  PubMed  Google Scholar 

  82. Petz LD, Yam P, Wallace RB, Stock AD, de Lange G, Knowlton RG et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood 1987; 70: 1331–1337.

    CAS  PubMed  Google Scholar 

  83. Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, Sok A, Drabczak-Skrzypek D et al. Association with the presence of naïve T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Transplant Proc 2007; 39: 2898–28901.

    CAS  PubMed  Google Scholar 

  84. Auffermann-Gretzinger S, Eger L, Bornhauser M, Schakel K, Oleschlaegel U, Schaich M et al. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation 2006; 81: 866–873.

    PubMed  Google Scholar 

  85. Yunis EJ, Zuniga J, Romero V, Yunis EJ . Chimerism and tetragametic chimerism in humans: implications in autoimmunity, allorecognition and tolerance. Immunol Res 2007; 38: 213–236.

    CAS  PubMed  Google Scholar 

  86. Kaufman DS, Thomson JA . Human ES cells—haematopoiesis and transplantation strategies. J Anat 2002; 200: 243–248.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Elva Mikk for valuable assistance in manuscript preparation.

Author information

Authors and Affiliations

  1. Department of Medicine, the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA

    J L Liesveld

  2. Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA

    P G Rothberg

Authors
  1. J L Liesveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P G Rothberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J L Liesveld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liesveld, J., Rothberg, P. Mixed chimerism in SCT: conflict or peaceful coexistence?. Bone Marrow Transplant 42, 297–310 (2008). https://doi.org/10.1038/bmt.2008.212

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.212

Keywords

This article is cited by

Search

Advanced search

Quick links